TrialCompass™ TCL
Back to trials
RecruitingPriority 4 · Lower priorityNCT05333367

MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy

ClinicalTrials.gov

Plain-language summary

This trial is testing Samples collection for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

Who can join (key eligibility)

  • Age 18 Years to 85 Years years
  • See full trial listing for complete eligibility

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Samples collection (OTHER): Sampling of 2 samples on the extracorporeal photochemotherapy circuit, before and after sensitization with 8-MOP and UVA irradiation (without additional puncture)

  • Samples collection

Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

Learn more

What is CTCL?

Plain-language overview of CTCL plus all curated trials for this subtype.

Use our AI Assistant

Ask questions about this trial, eligibility, or T-cell lymphoma in general.

Generate a letter for your doctor

Create a printable letter to discuss this trial with your oncologist.

TrialCompass — Clinical Trial Summary

MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy

NCT05333367

Status: Recruiting | Priority: Lower

Plain-language summary

This trial is testing Samples collection for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.

Who can join

  • Age 18 Years to 85 Years years
  • See full trial listing for complete eligibility

What's being tested

Samples collection (OTHER): Sampling of 2 samples on the extracorporeal photochemotherapy circuit, before and after sensitization with 8-MOP and UVA irradiation (without additional puncture)

Drugs / treatments: Samples collection

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 20 patients

Primary endpoint: Type of cell death induced by 8-MOP sensitization and UVA irradiation; Type of cell death induced by 8-MOP sensitization and UVA irradiation; Type of cell death induced by 8-MOP sensitization and UVA irradiation

Ages: 18 Years to 85 Years

Start date: 2022-04-15 | Est. completion: 2025-07

Locations

0 US sites · 1 total

Contact

Charline VAUCHY, PhD | cvauchy@chu-besancon.fr | +33381218875

Sponsor: Centre Hospitalier Universitaire de Besancon (OTHER)

Tags

CTCL · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT05333367

Prepared using TrialCompass (trialcompass.com) on August 3, 2026. For informational purposes only. Always discuss with your healthcare team.